Skip to main content

Table 1 Baseline clinical characteristics by age groups

From: Diabetic kidney disease in the elderly: prevalence and clinical correlates

 

All

< 65 years

65–75 years

> 75 years

n = 157,595

n = 58,238

n = 56,682

n = 42,675

Male sex

89,290 (56.7%)

35,941 (61.7%)

32,469 (57.3%)

20,880 (48.9%)

Age (years)

68 ± 11

57 ± 7

70 ± 3

80 ± 4

Known duration of diabetes (years)

11 ± 9

8 ± 7

12 ± 9

15 ± 11

Serum creatinine (mg/dL)

0.98 ± 0.54

0.88 ± 0.43

0.99 ± 0.54

1.10 ± 0.63

eGFR (mL/min/1.73m2)

76 ± 21

89 ± 18

74 ± 18

62 ± 19

Retinopathy

22,250 (14.1%)

6998 (12.0%)

8773 (15.5%)

6479 (15.2%)

BMI (Kg/m2)

29.6 ± 5.3

30.4 ± 5.8

29.6 ± 5.1

28.4 ± 4.7

HbA1c (%)

7.2 ± 1.3

7.3 ± 1.4

7.2 ± 1.2

7.2 ± 1.2

HbA1c

 7.0–7.4%

26,576 (17.1%)

9002 (15.7%)

10,057 (18.0%)

7517 (17.9%)

 7.5–8.5%

32,320 (20.8%)

11,265 (19.7%)

11,473 (20.5%)

9582 (22.8%)

  > 8.5%

20,993 (13.5%)

9214 (16.1%)

6401 (11.4%)

5378 (12.8%)

Total cholesterol (mg/dL)

177 ± 39

181 ± 40

175 ± 37

176 ± 38

Triglycerides (mg/dL)

137 ± 90

147 ± 108

133 ± 82

128 ± 69

HDL (mg/dL)

50 ± 14

48 ± 14

50 ± 14

51 ± 15

LDL (mg/dL)

101 ± 33

104 ± 34

99 ± 32

100 ± 33

Systolic BP (mmHg)

137 ± 18

134 ± 18

139 ± 18

140 ± 19

Diastolic BP (mmHg)

78 ± 9

79 ± 9

78 ± 9

76 ± 9

Smokers

14,793 (16.7%)

8865 (25.2%)

4435 (14.1%)

1493 (6.9%)

Cardiovascular therapy

 Lipid-lowering treatment

90,690 (57.5%)

31,402 (53.9%)

35,490 (62.6%)

23,798 (55.8%)

 Treatment with statins

83,342 (52.9%)

28,002 (48.1%)

32,928 (58.1%)

22,412 (52.5%)

 Treatment with fibrates

4588 (2.9%)

2285 (3.9%)

1503 (2.7%)

800 (1.9%)

 Antihypertensive treatment

112,424 (71.3%)

35,069 (60.2%)

43,031 (75.9%)

34,324 (80.4%)

 Treatment with ACE-Is/ARBs

95,821 (60.8%)

30,460 (52.3%)

36,938 (65.2%)

28,423 (66.6%)

 Aspirin

35,284 (22.4%)

9467 (16.3%)

14,278 (25.2%)

11,539 (27.0%)

Antidiabetic therapy

 Diet

8229 (5.2%)

3149 (5.4%)

3086 (5.4%)

1994 (4.7%)

 Oral antidiabetic drugs

100,535 (63.8%)

39,150 (67.2%)

36,379 (64.2%)

25,006 (58.6%)

 Oral antidiabetic drugs and insulin

26,634 (16.9%)

9460 (16.2%)

9906 (17.5%)

7268 (17.0%)

 Insulin

22,197 (14.1%)

6479 (11.1%)

7311 (12.9%)

8407 (19.7%)

Q Score

30 ± 8

30 ± 8

30 ± 8

29 ± 8

  < 15

5935 (3.8%)

2534 (4.4%)

1808 (3.2%)

1593 (3.7%)

 15–25

42,165 (26.8%)

15,375 (26.4%)

14,447 (25.5%)

12,343 (28.9%)

  > 25

109,495 (69.5%)

40,329 (69.2%)

40,427 (71.3%)

28,739 (67.3%)

  1. Mean ± SD or absolute frequency (percentage). ACE-Is = angiotensin converting enzyme-inhibitors, ARBs = angiotensin II receptor antagonists, BMI = body mass index, BP = blood pressure, eGFR = estimated glomerular filtration rate, HbA1c = glycated hemoglobin, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol. Patients’ missing data: known duration of diabetes in 8435 (5.4%), BMI in 14,918 (9.5%), HbA1c in 2291 (1.5%), total cholesterol in 8127 (5.2%), triglycerides in 10,293 (6.5%), HDL-c in 12,812 (8.1%), LDL-c in 13,495 (8.6%), blood pressure in 16,009 24,106 (15.3%), and smoking status in 69,213 (43.9%)